7/8/2022 8:39:51 AM
Innoviva Announces Expiration Of Cash Tender Offer For Shares Of Entasis Therapeutics Holdings
3/8/2022 7:59:46 AM
Wedbush Is Cutting Entasis Therapeutics Holdings Inc (ETTX) FY22 Estimate To -0.99 From -0.83
3/8/2022 7:59:29 AM
Wedbush Is Cutting Entasis Therapeutics Holdings Inc (ETTX) Q4 22 Estimate To -0.24 From -0.20
3/8/2022 7:59:18 AM
Wedbush Is Lowering Entasis Therapeutics Holdings Inc (ETTX) Q3 22 Estimate To -0.23 From -0.20
3/8/2022 7:58:56 AM
Wedbush Is Cutting Entasis Therapeutics Holdings Inc (ETTX) Q2 22 Estimate To -0.27 From -0.22
3/8/2022 7:58:42 AM
Wedbush Is Lowering Entasis Therapeutics Holdings Inc (ETTX) Q1 22 Estimate To -0.26 From -0.21
3/8/2022 7:57:38 AM
Wedbush Cuts Entasis Therapeutics Holdings Inc (ETTX) To Neutral From Outperform With $1.80 Down From $9 Price Target
4/2/2019 7:44:35 AM
Wedbush Is Increasing Entasis Therapeutics Holdings Inc (ETTX) FY19 Estimate To -2.75 From -3.34
4/2/2019 7:44:18 AM
Wedbush Is Increasing Entasis Therapeutics Holdings Inc (ETTX) Q4 19 Estimate To -0.63 From -0.81
4/2/2019 7:44:06 AM
Wedbush Is Increasing Entasis Therapeutics Holdings Inc (ETTX) Q3 19 Estimate To -0.59 From -0.76
4/2/2019 7:43:53 AM
Wedbush Is Raising Entasis Therapeutics Holdings Inc (ETTX) Q2 19 Estimate To -0.80 From -0.92
4/2/2019 7:43:33 AM
Wedbush Is Raising Entasis Therapeutics Holdings Inc (ETTX) Q1 19 Estimate To -0.74 From -0.85
10/22/2018 6:23:46 AM
Wedbush Initiates Entasis Therapeutics Holdings Inc (ETTX) At Outperform With $19 Price Target